Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects With Pulmonary Tuberculosis

NCT02467608 is registered in ClinicalTrials.gov with Orient Pharma Co., Ltd. as lead sponsor.

NCT NCT02467608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02467608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects With Pulmonary Tuberculosis
Lead sponsor
Orient Pharma Co., Ltd.
Phase
Phase 2/3
Overall status
Completed
Start date
December 6, 2012
Completion date
January 9, 2019
Enrollment
557 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary tuberculosis